Project Grant R01AG065596
- This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
- Federal Cooperative Agreement Award Summary Weill Medical College of Cornell University received a $3.25 million Cooperative Agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to conduct a Phase 1A clinical trial of gene therapy for Apolipoprotein E4 (APOE4) homozygous Alzheimer's disease. The award, effective April 1, 2026 through March 31, 2028, funds the development and administration of a novel adeno-associated virus (AAV)-based gene therapy...
- GRANT AWARD SUMMARY New York University School of Medicine received a $712,578 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective February 1, 2026, through December 31, 2030. The award funds a prospective epidemiological study designed to investigate the association between viral infections and subsequent risk of Alzheimer's disease (AD) using three prospective cohorts. The research employs VirScan, a bacteriophage...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $320,143 to Mayo Clinic to assess the diagnostic and disease biomarker utility of blood plasma measures in patients with atypical Alzheimer's disease (AD). The 2-year project aims to determine if plasma biomarkers can differentiate atypical AD patients from healthy controls and other clinical syndromes, as well as evaluate if the plasma biomarkers correlate with clinical...
- Federal Project Grant Award Summary New York University School of Medicine received a $724,813 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective January 1, 2026, through November 30, 2030. This award supports a prospective research investigation examining the relationship between circulating autoantibodies (AABs) measured at midlife and the risk of Alzheimer's disease (AD) in women. The research addresses a significant public health...
- Award Summary The National Institute on Aging awarded Brigham and Women's Hospital a $7.42 million Cooperative Agreement under the Aging Research program (CFDA 93.866) effective July 1, 2025, through June 30, 2030, to develop the Precision-AD Center. This initiative will establish a toolkit of two-dimensional and three-dimensional microphysiological systems (MPS) designed to model Alzheimer's disease and related dementias across genetically diverse populations. The project leverages induced...
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- This federal Project Grant award of $307,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a single, highly powered study to identify memory processes that are most sensitive to the asymptomatic, preclinical stage of Alzheimer's disease (AD) pathology. The study combines a continuous report item-location associative memory task with advanced behavioral and neural modeling to estimate subtle changes in memory precision that may differentiate healthy...
- The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...
SERUM PROTEOME ANALYSIS OF ALZHEIMER?S DISEASE IN A POPULATION-BASED LONGITUDINAL COHORT STUDY - THE AGES REYKJAVIK STUDY - PROTEINS ARE THE KEY PLAYERS IN ALL LIFE PROCESSES, IN HEALTH AND DISEASE, AND THE VAST MAJORITY OF DRUG TARGETS ARE PROTEINS. HIGH THROUGHPUT DETECTION AND QUANTIFICATION OF THE PROTEOME IN COMPLEX TISSUES SUCH AS BLOOD HAS HISTORICALLY BEEN HAMPERED BY THE LIMITATIONS OF AVAILABLE METHODS. RECENT PROGRESS ALLOWS PROTEOMICS TO BE MEASURED IN LARGE POPULATIONS. AN APTAMER-BASED PROTEOMICS PLATFORM WAS RECENTLY DEVELOPED TO MEASURE 4137 PROTEINS IN THE SERUM OF 5457 INDIVIDUALS FROM THE PHENOTYPICALLY AND GENETICALLY WELL-CHARACTERIZED POPULATION-BASED AGES REYKJAVIK STUDY, OF WHICH 3289 PARTICIPATED IN A FIVE-YEAR FOLLOW-UP STUDY. WE HAVE SHOWN THAT SERUM PROTEINS CLUSTER INTO CO-REGULATORY NETWORKS THAT WERE ALIGNED WITH COMMON DISEASES AND AS INTERMEDIARIES BETWEEN GENETIC VARIATION DRIVING DISEASE AND WITH THE APPEARANCE OF DISEASE ACROSS THE POPULATION. IN THE PROPOSED STUDY, W E WILL LEVERAGE GENETICS, PROTEOMICS AND NETWORK-BASED DATA ACROSS MULTIPLE BRAIN RELATED OUTCOMES, USING BOTH CROSS-SECTIONAL AND LONGITUDINAL STUDY DESIGN, TO DESCRIBE THE RELATIONSHIPS OF GLOBAL SERUM PROTEINS TO EACH OTHER, TO GENETICS AND TO LATE-ONSET ALZHEIMER'S DISEASE (LOAD). WITH INCREASING AGING OF THE POPULATION THE PREVALENCE OF LOAD IS ON THE RISE, MAKING EFFECTIVE LOAD TREATMENT ONE OF THE FASTEST GROWING UNMET MEDICAL NEEDS IN GLOBAL HEALTHCARE SYSTEMS. WE PROPOSE THREE DIFFERENT AIMS. IN AIM 1, WE WILL EXAMINE THE ASSOCIATION OF 4137 SERUM PROTEINS AS WELL AS AMYLOID-SS PEPTIDES AND PROTEIN NETWORKS, AT BASELINE AND FIVE YEARS LATER, TO PREVALENT AND INCIDENT LOAD. IN AIM 2, WE WILL DETERMINE ASSOCIATION OF THE 4137 SERUM PROTEINS TO STRUCTURAL BRAIN MRI BIOMARKERS OF NEURODEGENERATION FOR FURTHER LINKS TO LOAD AND BRAIN ATROPHY PROGRESSION RATES. IN AIM 3, WE WILL ADDRESS CAUSALITY BETWEEN PROTEINS AND LOAD THROUGH BI-DIRECTIONAL MENDELIAN RANDOMIZATION ANALYSIS, USING VARIANTS THAT REGULATE SERUM PROTEINS AS GENETIC INSTRUMENTS. TO OUR KNOWLEDGE THIS IS THE LARGEST PROTEOMICS DATA SET TO DATE AS REGARDS NUMBER OF PROTEINS MEASURED AND SAMPLES SCREENED. THE PROPOSED PROJECT IS SIGNIFICANT FOR MANY REASONS INCLUDING FOR INSTANCE: I. THE LARGE-SCALE PROTEOMICS DATA INTEGRATED WITH VARIATION IN THE GENOME AND DEEP PHENOME DATA FACILITATES SYSTEMS APPROACHES TO LOAD. II. THE APPLICATION OF LONGITUDINAL DATA TO ASSESS INTRA-INDIVIDUAL CHANGES IN PROTEIN BIOMARKER LEVELS OVER TIME ON LONG-TERM LOAD RELATED OUTCOMES OFFERS UNIQUE OPPORTUNITIES FOR ROBUST BIOMARKER DISCOVERIES IN LOAD. III. WHOLE GENOME ANALYSIS OF GLOBAL SERUM PROTEINS WILL PROVIDE THE SCIENTIFIC COMMUNITY WITH A NOVEL SOURCE OF GENETIC INSTRUMENTS FOR TESTS OF CAUSALITY AND TO REVEAL THE CAUSAL MECHANISM(S) UNDERLYING THE RISK OF LOAD. IN SUMMARY, THE RESULTS OF THE PROPOSED PROJECT WILL OFFER A HOLISTIC MODEL OF THE ETIOLOGY OF LOAD YIELDING NOVEL BIOMARKERS AND POINT TO ACTIONABLE TARGETS FOR TREATING THE DISEASE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $549.2k | 4/7/26 | ||
| Not listed | $589.2k | 5/7/25 | ||
| Not listed | ($11k) | 12/14/23 | ||
| Not listed | ($11k) | 12/14/23 | ||
| Not listed | $704.5k | 5/11/22 |